The 90 million euros ($94 million) raised by Orbis Medicines in a series A round was not January’s biggest venture investment ...

The US Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for brensocatib for patients with ...

US pharma giant Pfizer (NYSE: PFE) today announced that Jeffrey Legos will join the company as chief oncology officer.

Shares in US retinal diseases specialist EyePoint Pharmaceuticals recovered from an early nosedive to close trading ...

Swiss drug developer Basilea Pharmaceutica reported that the sales of the antifungal Cresemba (isavuconazole) in Japan ...

US pharma major Eli Lilly today announced its financial results for the fourth quarter of 2024 and detailed 2025 financial ...

Anglo-Swedish pharma major AstraZeneca beat analyst expectations in presenting its impressive latest financial results.

California, USA-based rare disease company Ultragenyx Pharmaceutical yesterday released new data demonstrating treatment with UX111 (ABO-102) AAV gene therapy led to a statistically-significant ...

Kura Oncology and Japan’s Kyowa Kirin have announced that their menin inhibitor ziftomenib met the primary endpoint in a ...

US health technology assessor the Institute for Clinical and Economic Review (ICER) yesterday posted its revised Evidence Report assessing the comparative clinical effectiveness and value of ...

US clinical-stage biotech Qlaris Bio has announced positive top-line results from two U.S. Phase II clinical trials ...

The New England Journal of Medicine has published results from the Phase II eNRGy trial for Bizengri (zenocutuzumab), a novel cancer med from Merus. Bizengri is the first approved treatment for people ...